Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2026-05-24 Delisting Announcement
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Receipt of Staff Delist Determination from Nasdaq
Delisting Announcement Classification · 90% confidence The document is a Form 6-K by XTL Biopharmaceuticals furnishing a press release (Exhibit 99.1) titled “XTL Announces Receipt of Staff Delist Determination from Nasdaq,” detailing Nasdaq’s notice and potential delisting process. This is a direct announcement regarding removal of the company’s securities from an exchange, fitting the Delisting Announcement category.
2026-05-24 English
Receipt of Staff Delist Determination from Nasdaq
Report Publication Announcement Classification · 78% confidence The document is an Immediate Report under Israeli Securities Regulations notifying the exchange and ISA of the company’s failure to file its 2025 financial statements. The body text is only a notice with metadata and the filename of the attached report (ea029190401-6k_xtlbioEDGAR1_Bannerless_isa.pdf), without any substantive financial content. It fits the “menu vs. meal” rule: a short announcement (<5,000 chars) stating that a report is attached, rather than the report itself. Therefore, per the definitions, it should be classified as a Report Publication Announcement (RPA).
2026-05-24 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2026-05-22 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a SEC Form 6-K reporting that XTL Biopharmaceuticals Ltd. is furnishing shareholders with the Notice of Extraordinary General Meeting of Shareholders and the accompanying Proxy Statement and proxy card. The text includes detailed voting instructions, agenda items for the EGM, and solicitation procedures – all hallmarks of a Proxy Solicitation & Information Statement. Therefore, this falls squarely under the Proxy Solicitation & Information Statement category.
2026-05-16 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement Classification · 80% confidence The document is an Immediate Report of Convening an Extraordinary General Meeting, detailing the agenda items and providing voting instructions via the Voting System. It is not reporting voting results, financial data, or management changes; rather it is a notice sent to shareholders to inform them of the meeting and solicit their votes. This matches the definition of Proxy Solicitation & Information Statement (PSI).
2026-05-16 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2026-05-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.